The Burden of Health-Related Out-of-Pocket Cancer Costs in Canada: A Case-Control Study Using Linked Data.

cancer cancer registry data equity health-related out-of-pocket cost burden out-of-pocket costs survey data

Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
27 06 2022
Historique:
received: 08 04 2022
revised: 02 06 2022
accepted: 20 06 2022
entrez: 25 7 2022
pubmed: 26 7 2022
medline: 28 7 2022
Statut: epublish

Résumé

The burden of out-of-pocket costs among cancer patients/survivors in Canada is not well understood. The objective of this study was to examine the health-related out-of-pocket cost burden experienced by households with a cancer patient/survivor compared to those without, examine the components of health-related costs and determine who experiences a greater burden. This study used a data linkage between the Survey of Household Spending and the Canadian Cancer Registry to identify households with a cancer patient/survivor (cases) and those without (controls). The out-of-pocket burden (out-of-pocket costs measured relative to household income) and mean costs were described and regression analyses examined the characteristics associated with the household out-of-pocket burden and annual out-of-pocket costs. The health-related out-of-pocket cost burden and annual costs measured in households with a cancer patient/survivor were 3.08% (95% CI: 2.55-3.62%) and CAD 1600 (95% CI: 1456-1759), respectively, compared to a burden of 2.84% (95% CI: 2.31-3.38) and annual costs of CAD 1511 (95% CI: 1377-1659) measured in control households, respectively. Households with a colorectal cancer patient/survivor had a significantly higher out-of-pocket burden compared to controls (mean difference: 1.0%, 95% CI: 0.18, 0.46). Among both cases and controls, the lowest income quintile households experienced the highest health-related out-of-pocket cost burden. Within a universal health care system, it is still relevant to monitor health-related out-of-pocket spending that is not covered by existing insurance mechanisms; however, this is not routinely assessed in Canada. We demonstrate the feasibility of measuring such costs in households with a cancer patient/survivor using routinely collected data. While the burden and annual health-related out-of-pocket costs of households with a cancer patient/survivor were not significantly higher than control households in this study, the routine measurement of out-of-pocket costs in Canada could be systemized, providing a novel, system-level, equity-informed performance indicator, which is relevant for monitoring inequities in the burden of out-of-pocket costs.

Sections du résumé

BACKGROUND
The burden of out-of-pocket costs among cancer patients/survivors in Canada is not well understood. The objective of this study was to examine the health-related out-of-pocket cost burden experienced by households with a cancer patient/survivor compared to those without, examine the components of health-related costs and determine who experiences a greater burden.
DATA AND METHODS
This study used a data linkage between the Survey of Household Spending and the Canadian Cancer Registry to identify households with a cancer patient/survivor (cases) and those without (controls). The out-of-pocket burden (out-of-pocket costs measured relative to household income) and mean costs were described and regression analyses examined the characteristics associated with the household out-of-pocket burden and annual out-of-pocket costs.
RESULTS
The health-related out-of-pocket cost burden and annual costs measured in households with a cancer patient/survivor were 3.08% (95% CI: 2.55-3.62%) and CAD 1600 (95% CI: 1456-1759), respectively, compared to a burden of 2.84% (95% CI: 2.31-3.38) and annual costs of CAD 1511 (95% CI: 1377-1659) measured in control households, respectively. Households with a colorectal cancer patient/survivor had a significantly higher out-of-pocket burden compared to controls (mean difference: 1.0%, 95% CI: 0.18, 0.46). Among both cases and controls, the lowest income quintile households experienced the highest health-related out-of-pocket cost burden.
INTERPRETATION
Within a universal health care system, it is still relevant to monitor health-related out-of-pocket spending that is not covered by existing insurance mechanisms; however, this is not routinely assessed in Canada. We demonstrate the feasibility of measuring such costs in households with a cancer patient/survivor using routinely collected data. While the burden and annual health-related out-of-pocket costs of households with a cancer patient/survivor were not significantly higher than control households in this study, the routine measurement of out-of-pocket costs in Canada could be systemized, providing a novel, system-level, equity-informed performance indicator, which is relevant for monitoring inequities in the burden of out-of-pocket costs.

Identifiants

pubmed: 35877219
pii: curroncol29070359
doi: 10.3390/curroncol29070359
pmc: PMC9322389
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4541-4557

Références

Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2006-14
pubmed: 21980008
Clin Lung Cancer. 2019 Jul;20(4):231-236
pubmed: 30797721
J Cancer Surviv. 2014 Mar;8(1):9-20
pubmed: 23975612
BMC Cancer. 2016 Oct 18;16(1):809
pubmed: 27756310
Curr Oncol. 2013 Jun;20(3):158-65
pubmed: 23737684
Palliat Med. 2015 Dec;29(10):908-17
pubmed: 26040484
J Psychosoc Oncol. 2018 Sep-Oct;36(5):582-596
pubmed: 30235067
CMAJ Open. 2018 Jan 4;6(1):E1-E10
pubmed: 29301745
Curr Oncol. 2011 Jan;18(1):e1-8
pubmed: 21331267
Support Care Cancer. 2020 Oct;28(10):4645-4665
pubmed: 32653957
CMAJ. 2020 Mar 2;192(9):E199-E205
pubmed: 32122974
Support Care Cancer. 2021 Jun;29(6):3377-3386
pubmed: 33403399
J Natl Cancer Inst. 2013 Feb 20;105(4):280-92
pubmed: 23349250
Oncology (Williston Park). 2013 Feb;27(2):80-1, 149
pubmed: 23530397
Support Care Cancer. 2019 Aug;27(8):2977-2986
pubmed: 30588549
EClinicalMedicine. 2020 Jan 31;20:100269
pubmed: 32300733
Lancet Oncol. 2012 Aug;13(8):790-801
pubmed: 22658655
Health Soc Care Community. 2015 Nov;23(6):605-18
pubmed: 25443659
Curr Oncol. 2021 Mar 15;28(2):1216-1248
pubmed: 33804288
Lancet. 2018 May 19;391(10134):2047-2058
pubmed: 29627161
Lancet Oncol. 2013 Nov;14(12):1165-74
pubmed: 24131614

Auteurs

Beverley M Essue (BM)

Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada.
Canadian Partnership Against Cancer, Toronto, ON M5H 1J8, Canada.

Claire de Oliveira (C)

Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada.
Canadian Partnership Against Cancer, Toronto, ON M5H 1J8, Canada.
Centre for Health Economics and Hull York Medical School, University of York, Heslington, York YO10 5DD, UK.
Centre for Addiction and Mental Health, Institute for Mental Health Policy Research, Toronto, ON M6J 1H4, Canada.

Tracey Bushnik (T)

Health Analysis Division, Statistics Canada, Ottawa, ON K1A 0T6, Canada.

Sharon Fung (S)

Canadian Partnership Against Cancer, Toronto, ON M5H 1J8, Canada.

Jeremiah Hwee (J)

Health Analysis Division, Statistics Canada, Ottawa, ON K1A 0T6, Canada.

Zhuolu Sun (Z)

Canadian Partnership Against Cancer, Toronto, ON M5H 1J8, Canada.

Elba Gomez Navas (EG)

Canadian Partnership Against Cancer, Toronto, ON M5H 1J8, Canada.

Jean Hai Ein Yong (JHE)

Canadian Partnership Against Cancer, Toronto, ON M5H 1J8, Canada.

Rochelle Garner (R)

Health Analysis Division, Statistics Canada, Ottawa, ON K1A 0T6, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH